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Purpose. To report data which happened to be observed in two glaucoma patients treated with Cord Blood Serum (CBS) eye drops.
Design. A case report and retrospective data analysis. Methods. CBS topical eye drops, characterized in advance for growth factors
(GFs) content, were administered for two months with the aim to relieve their subjective symptoms, in two patients who had
referred ocular surface discomfort, although in absence of any sign of keratopathy. As patients were also affected by advanced
glaucoma at risk of vision loss and under treatment with hypotensive drugs, they had been also monitored over the same period
with IOP controls and visual field tests in our unit. Results. During subsequent visits, data from Mean Deviation and Pattern
Standard Deviation in the visual fields were retrospectively collected and compared with before and after treatment with CBS, and
an amelioration was observed. Conclusions. CBS contains a combination of GFs, which potentially exert a neuroprotective action
and elect CBS as an interesting natural source to be delivered in neurodegenerative ocular disorders. The incidentally observed
amelioration in these two patients deserves further investigation in this respect.
1. Introduction
The term glaucoma identifies a group of ocular multifactorial
pathologies with the characteristic triad of the intraocular
pressure (IOP) increase, degenerative phenomena affecting
the optic nerve head, and a progressive deterioration of
the visual field. Some forms of glaucomatous neuropathy
are however diagnosed without clinical evidence of ocular
hypertension, and also progressive visual loss in glaucoma
may occur even with pharmaceutical controlled IOP values.
The disease is now increasingly seen as one of the
central nervous system age-related neurodegenerations [1,
2]. Taking into account both the presence of normotensive
glaucoma and the recent observations on the presence of
neurotoxic waste in glaucomatous subjects which might
induce downstream events like oxidative stress [3], glial
activation [4], neurotrophin deprivation [5], and mitochon-
drial dysfunction [6, 7] it seems possible to hypothesize
that glaucoma is a multifactorial neurodegenerative disease
where the main outcome is represented by ganglion cells
death [2]. Accordingly it is becoming a relevant issue to test
neuroprotective agents in patients with glaucoma to slow
down or even block the progression of the disease [8, 9].
In the present paper incidentally observed data are
reported on two patients who had been treated with Cord
Blood Serum (CBS) eye drops prescribed with the aim to
relieve their subjective symptoms of surface discomfort.
It is well known that the cord blood is rich with trophic
factors whose content might vary according to several unpre-
dictable parameters probably during gestation and labor [10,
11]. Recently CBS has been used as eye drops for pathologies
related to cornea but the possibility that such a mixture of
factors might be useful even in retinal disease exists and
deserves to be tested [12, 13].
Preliminary results from these cases provide evidence
of a positive outcome of experimental hypothesis, as CBS
eye drop treatment efficiently ameliorates visual field in
glaucomatous patients.
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Table 1: Levels of growth factors contained in the CBS eye drops administered to patient n.1, for the first and second month of treatment,
respectively. EGF: epidermal growth factor; TGF-!: transforming growth factor; b-NGF: basic nerve growth factor; PDGF-bb: platelet-derived
growth factor; b-FGF: basic fibroblast growth factor; and IL: interleukin.
month EGF TGF-! b-NGF PDGF-bb∗ b-FGF IL-10 IL-13
Lot n.1 first 152.7 15.7 2.0 1.99 104.2 1.8 41.4
Lot n.2 second 148.8 12.8 1.7 1.75 76.9 1.5 25.0
Case n.1: values expressed in pg/ml sample, except for ∗= ng/ml.
1.1. Treatment. Cord Blood Serum (CBS) eye drops had
been prepared as previously described in detail [12] for
epithelial healing purpose. Briefly, the umbilical cord blood
(UCB) was obtained from mothers with vaginal or cesarean
section delivery after informed consent, and all steps were
performed according to standard operating procedures and
guidelines edited by the Foundation for the Accreditation of
Hematopoietic Cellular Therapy (FACT). For the purpose of
preparing eye drops, blood samples were collected from ex
utero placenta vessels and were clotted for 2 hours at room
temperature, centrifuged, and frozen at -80∘C for quarantine
period. After this period sera were thawed, pooled, diluted
by 20% in sterile PBS, filtered, finally aliquoted into COL-20
medical device (Biomed, Modena, Italy) in single dose one-
day vials, packed, frozen, and stored at -80∘C.
One aliquot in each lot had been retained for further
testing of selected growth factors (GFs), in particular IL-
10, IL-13, basic FGF, PDGF-bb, b-NGF, EGF, and TGF-!. Samples were evaluated by using commercially available
multiplex bead-based sandwich immunoassay kits (Bio-Rad
Laboratories, CA, USA), by means of the Bio-Plex Protein
Array System (Bio-Rad Laboratories, CA, USA) as detailed
elsewhere [14].
1.2. Case Presentation. The setting of this study was the
Ophthalmic Unit at S.Orsola-Malpighi Teaching Hospital,
Alma Mater, Studiorum University of Bologna, where the
treatment with CBS topical eye drops is a therapeutic option
in patients suffering from dry eye associated with severe sub-
jective symptoms of discomfort [12]. In the period of March-
September 2016, two patients who had referred ocular sur-
face discomfort unresponsive to previous therapy, although
in absence of any sign of keratopathy, were administered
with CBS topical eye drops for a total of two months. As
patients were also affected by POAG and under treatment
with hypotensive drugs, they had been also monitored over
the same period with IOP controls and visual field tests
in our unit. Data from the retrospective analyses of these
examinations and of the back history of these patients is here
described.
1.3. Case 1. Patient n. 1 was a 66-year old male, suffering
from diabetes type I, requiring insulin therapy since 2006.
The patient also presented associated diabetic retinopathy,
and a primary open angle glaucoma (POAG) had been
diagnosed in January 2014. Values of IOP were successfully
maintained within normal range with hypotensive topical
drugs. In January 2016, the patient had referred to increasing
irritating symptoms of eye discomfort, described as burning,
itchiness, and feeling sand in his eyes, scored asOSDI (Ocular
Surface Disease Index) [15] of 65 out of 100, with a VAS
(Visual Analogue Score) [16] score of pain of 74mmout of 100
and no difference between eyes. Slit lamp evaluation had not
shown epithelial damage, also with the aid of fluorescein vital
stain observed with the blue cobalt filter, and there were no
signs of inflammation, but only a reducedTear FilmBreak-Up
Time (TFBUT) of 7 seconds in both eyes had been recorded.
A therapy with hyaluronic acid (HA) based tear substitute to
be administered 4 times/day in both eyes was prescribed.
At a subsequent visit inApril 2016, the patient reported no
relief from severe symptoms (OSDI: score 62 out of 100, VAS:
80 out of 100mm)which remained severe, despite the regular
administration of HA, increased from 4 to multiple times
each day. As recorded from the history of the patient’s charts,
previous therapy with anti-inflammatory drugs had turned
to be unsuccessful, and inMay 2016 the patient was proposed
to receive a treatment with topical CBS, as a compassionate
unconventional therapy.The rationale for this therapy was to
reduce the pain symptoms for which the previous therapeutic
attempts had turned to be unsuccessful.
The patient signed the informed consent, specifically
designed for this purpose, and started administration of the
CBS eye drops in June 2016, with the posology of 0.4 ml (8
drops) in each eye, each day for a total of two months. In
Table 1 the GF dosages determined for the two CBS lots were
administered during the first and secondmonth of treatment.
In September 2016, the patient reported a significant relief
from subjective symptoms of discomfort. OSDI score was
reduced: 24 out of 100 and VAS was also reduced: 35mm out
of 100. During this visit, the IOP resulted in the normal range,
and the analyses of the visual field tests performed since 2014
were carried out.
In Figure 1 the mean deviation (MD) values recorded in
January 2014, June 2016, and September 2016 were graphed.
A significant lowering in MD values was observed which
was followed by an amelioration in correspondence with
the period of treatment with CBS, in the figure highlighted
with the arrow. In Figure 2 the central 30-2 visual field tests
before ((a) right eye RE; (b) left eye LE) and after (c, d) the
CBS treatment were shown. An amelioration of the defect
was observed in all the four quadrants in both eyes, as it
is demonstrated by the unvaried Pattern Standard Deviation
(PSD) values.
1.4. Case 2. Patient n. 2 was a 60-year old female, diagnosed
with suffering fromPOAG for ten years, under treatmentwith
hypotensive drugs and regularly controlled IOP twice a year
which appeared maintained within normal ranges. During


















































































































Figure 1: Patient 1. Trend of the mean deviation (MD) from January 2014 to September 2016.The arrow indicates the beginning of treatment





















Figure 2: Patient 1. Central 30-2 visual field test recorded in June 2016 (a, b) and September 2016 (c,d), in right (RE) and left (LE) eye.
a control visit in January 2016, the patient had reported
irritating symptoms of eye discomfort, described as burning,
itchiness, and feeling sand, mainly in her right eye (RE), over
the last six months. The situation had been managed with
the use of several types of tear substitutes, none of them
successful in symptom relief. Symptoms were scored in the
RE as OSDI of 74 out of 100 and a VAS score of pain of 85
mmout of 100. In the left eye (LE) the symptoms were defined
by the patients as light and acceptable: OSDI score was 22
out of 100 and VAS 21 mm out of 100. Slit lamp evaluation
had not shown epithelial damage, and there were no signs of
inflammation, but only a reduced Tear Film Break-Up Time
(TFBUT) of 4 seconds in RE and 8 seconds in LE had been
recorded. A therapy with hyaluronic acid (HA) based tear
substitute to be administered 4 times/day in both eyes was
prescribed.
In March 2016, the patient was proposed to receive in
her RE a treatment with topical CBS, as a compassionate
unconventional therapy, with the aim to reduce the pain
symptoms for which the previous therapeutic attempts had
turned to be unsuccessful. The therapy for the contralateral
LE was maintained with HA based tear substitutes.
The patient signed the specifically designed informed
consent and started administration of the CBS eye drops in
April 2016, with the posology of 0.4ml (8 drops) in RE, each
day for a total of two months. In Table 2 the GF dosages
determined for the two CBS lots were administered during
the first and second month.
On September 2016, the patient reported a significant
relief from subjective symptoms of discomfort; in RE the
OSDI was 28 out of 100, with VAS: 32mm out of 100. Also in
LE a reduction was observed, with OSDI score determined as
16 out of 100 and VAS 15mmout of 100. During this visit, also
the IOP was measured, which resulted in the normal range in
both eyes and the analyses of the visual field tests performed
since 2006.
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Table 2: Levels of growth factors contained in the CBS eye drops administered to patient n.2, for the first and second month of treatment,
respectively. EGF: epidermal growth factor; TGF-!: transforming growth factor; b-NGF: basic neural growth factor; PDGF-bb: Platelet-
derived growth factor; b-FGF: basic fibroblast growth factor; and IL: interleukin.
months EGF TGF-! b-NGF PDGF-bb∗ b-FGF IL-10 IL-13
Lot n.3 first 232.5 19.3 1.4 1.94 96.4 2.9 62.4
Lot n.4 second 242.6 19.8 1.2 2.43 44.3 1.2 27.9











































































































Figure 3: Ten-year trend of themean deviation (MD), fromDecem-
ber 2006 to September 2016. The arrow indicates the beginning of










































































































Figure 4: Ten-year trend of the Pattern Standard Deviation (PSD),
from December 2006 to September 2016. The arrow indicates the
beginning of treatment with CBS eye drop. RE: right eye; LE: left
eye.
In Figure 3 the mean deviation (MD) values recorded
over several visits performed from December 2006 through
September 2016 were graphed. A significant progressive
lowering in MD values was observed which was followed by
an important amelioration in correspondencewith the period
of treatment with CBS, in the figure highlighted with the
arrow. It has to be noted that the increase in MD values was
recorded either in the treated right eye or in the untreated left
eye. Moreover, the MD values recorded in September 2016,
fourmonths after the end of theCBS eye drop administration,
showed in both eyes a further amelioration.
The improvement is also demonstrated by the analysis
of the PSD shown in Figure 4. A progressive worsening in
PSD values had been observed over ten years, whereas a
rapid change was recorded in correspondence with the CBS
eye drop treatment, either in the treated right eye or in the
untreated left eye.
In Figure 5 the central 30-2 visual field tests before ((a):
right eye RE; (b): left eye LE), at the end (c, d) and after four
months (e, f) from the end of the CBS eye drop treatment
were shown. An amelioration of the defect was observed in all
the four quadrants in both the treated RE and the untreated
LE.
Taking together these observations, a positive effect also
in the left untreated eye could be recorded, which suggests a
neural cross-talk mechanism between the eyes.
2. Discussion
Neuroprotective treatment in degenerative ophthalmological
diseases is currently proposed by the administration of natu-
ral products such as Crocins from saffron [17] or specific syn-
thetized molecules such as Memantine [18], Citicoline [19],
Brimonidine [20, 21], Homotaurine [22], and Polyphenols
[23, 24]. Clinical studies related to neuroprotection in ocular
diseases are at an early stage and although promising it is
difficult to figure out whether neuroprotective approach will
have useful clinical developments in the near future. In fact,
unfortunately, almost all clinical trials of neuroprotection in
ophthalmologic disease have failed to show efficacy so far,
despite encouraging preclinical studies [25, 26].
This report demonstrated that topical CBS eye drops
administered for two months in two patients suffering from
glaucoma determined an amelioration of parameters from
visualfield test, as compared to before and after the treatment.
Among neuroprotective agents to be tested, the possibility of
using growth factors from cord blood arises from a variety
of observation in preclinical and clinical studies, for instance,
in amyotrophic lateral sclerosis [27]. We had determined in
the CBS eye drops the levels of GFs involved in promoting
corneal epithelial healing, but some of them had also been
shown to exert neuroprotection mechanism in experimental
models of glaucoma, such as TGF-! [28], b-NGF [29],
and PDGF-bb [30]. The report only allows us to speculate
that these GFs, potentially in a synergic action with others
not tested specifically on this occasion, may have played
a role in the amelioration of the visual field parameters.
Another speculation relates to the amelioration effect in the
contralateral untreated eye of patient n.2. The possibility
arises that the bilateral response might be a consequence of
cross-talk between eyes which could be further discussed.We
considered our findings from these two patients a serendipity































Figure 5: Patient 2. Central 30-2 visual field test recorded in March 2016 (a, b) before the start of CBS treatment, June 2016 (c,d) at the end
of CBS treatment, and September 2016 (e, f) after four months from the end of CBS treatment, in right (RE) and left (LE) eye.
with high potential to be expanded on a more numerous and
prospective basis.
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